Сердечно-сосудистые осложнения иммунотерапии гематологических злокачественных опухолей (обзор литературы)

Q4 Medicine

Klinicheskaya Onkogematologiya/Clinical Oncohematology Pub Date : 2023-09-02 DOI:10.21320/2500-2139-2023-16-4-407-412

Гелия Рифкатовна Гиматдинова, О. Е. Данилова, В. П. Кузьмин, Г. И. Давыдкин, Ю. В. Косталанова, Д. А. Кудлай, И. Л. Давыдкин

{"title":"Сердечно-сосудистые осложнения иммунотерапии гематологических злокачественных опухолей (обзор литературы)","authors":"Гелия Рифкатовна Гиматдинова, О. Е. Данилова, В. П. Кузьмин, Г. И. Давыдкин, Ю. В. Косталанова, Д. А. Кудлай, И. Л. Давыдкин","doi":"10.21320/2500-2139-2023-16-4-407-412","DOIUrl":null,"url":null,"abstract":"In clinical oncology in general, tumor treatment is closely related to a highly relevant issue of chemotherapy-induced adverse events. Among side effects, cardiovascular toxicity occupies the foremost place. The strategy of controlling the cardiovascular complications associated with antitumor drug and cell therapies presupposes an early diagnosis of changes in the heart muscle and blood vessels at the stage of subclinical manifestations of adverse events. The present literature review provides the analysis of data on immunotherapy side effects in hematological malignancies with a focus on cardiovascular complications. The review comprehensively discusses the characteristics of cardiovascular complications associated with immune checkpoint inhibitors, CAR-T cell products, bispecific antibodies as well as immunomodulatory and antiangiogenic drugs.","PeriodicalId":36905,"journal":{"name":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","volume":"38 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicheskaya Onkogematologiya/Clinical Oncohematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21320/2500-2139-2023-16-4-407-412","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

In clinical oncology in general, tumor treatment is closely related to a highly relevant issue of chemotherapy-induced adverse events. Among side effects, cardiovascular toxicity occupies the foremost place. The strategy of controlling the cardiovascular complications associated with antitumor drug and cell therapies presupposes an early diagnosis of changes in the heart muscle and blood vessels at the stage of subclinical manifestations of adverse events. The present literature review provides the analysis of data on immunotherapy side effects in hematological malignancies with a focus on cardiovascular complications. The review comprehensively discusses the characteristics of cardiovascular complications associated with immune checkpoint inhibitors, CAR-T cell products, bispecific antibodies as well as immunomodulatory and antiangiogenic drugs.

查看原文本刊更多论文

血液恶性肿瘤免疫治疗的心血管并发症(文学评论)

在临床肿瘤学中，肿瘤治疗与化疗引起的不良事件密切相关。在副作用中，心血管毒性占据首位。控制与抗肿瘤药物和细胞治疗相关的心血管并发症的策略，以在不良事件的亚临床表现阶段早期诊断心肌和血管的变化为前提。目前的文献综述提供了数据分析免疫治疗的副作用在血液系统恶性肿瘤，重点是心血管并发症。本文全面讨论了与免疫检查点抑制剂、CAR-T细胞产物、双特异性抗体以及免疫调节和抗血管生成药物相关的心血管并发症的特点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊